Anticancer research
-
Anticancer research · Sep 2000
Comparative StudyTechnetium-99m methoxy-isobutyl-isonitrile chest single photon emission computed tomography to detect mediastinal lymph node metastasis in patients with non-small cell lung cancer: comparison with computed tomography.
This study evaluated the clinical role of Tc-99m-methoxyisobtylisonitrile (Tc-MIBI) single photon emission computed tomography (SPECT) of the chest in the detection of mediastinal lymph node (MLN) metastasis in patients with non-small cell lung cancer (NSCLC). Twenty-five patients with proven NSCLC were enrolled in this study. Each of the patients received computed tomography (CT) of the chest and Tc-MIBI SPECT of the chest for presurgical staging. ⋯ Meanwhile, 10 volunteers also accepted Tc-MIBI SPECT of the chest for comparison. The results showed that the diagnostic sensitivity, specificity and accuracy of Tc-MIBI chest SPECT were 81.8%, 85.7% and 84% and for chest CT they are 36.3%, 85.7% and 64%, respectively. Our results indicated that Tc-MIBI chest SPECT was more sensitive and accurate than chest CT in the evaluation and detection of MLN involvement in the NSCLC patients.
-
Anticancer research · Sep 2000
Randomized Controlled Trial Comparative Study Clinical TrialAdjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
CMF and Tamoxifen are the most commonly administered drugs for the adjuvant treatment of early-stage breast cancer. We present the 15-year follow-up of our 250-patient series and evaluate the oestrogenic side-effect of Tamoxifen on the endometrium. ⋯ CMF + Tamoxifen combination offers better long-term results for early-stage breast cancer patients. Dose reduction must be avoided if maximum results are to be achieved. More than 4 positive nodes seem to require additional chemotherapeutic manipulation. Tamoxifen's oestrogenic side-effect on the endometrium is quite common, but life-threatening lesions are rare, thus proving the drug's safety.
-
Anticancer research · Sep 2000
Randomized Controlled Trial Multicenter Study Clinical TrialRandomized controlled trial of 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration and HCFU alone as postoperative adjuvant chemotherapy for colorectal cancer.
Although surgical resectability is an important prognostic factor, recurrences are commonly noted in advanced colorectal cancer patients, even after apparently curative surgery. Because such recurrences cannot be cured, better adjuvant chemotherapies are urgently required. ⋯ Inductive therapy with 5-FU in combination with oral HCFU is beneficial as adjuvant chemotherapy for advanced colorectal cancer with lymph node metastasis.
-
Anticancer research · Sep 2000
Inhibitory effects of active substances isolated from Cassia garrettiana heartwood on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice (Part 1).
A methanol extract (500 mg/kg x 2/day) of the heartwood of Cassia garrettiana inhibited the tumor growth and metastasis to the lung in Lewis lung carcinoma (LLC)-bearing mice. We isolated the two active substances from the methanol extract of C. garrettiana: compound 1 was identified as Cassigarol A and the determination of the structure of compound 2 is now in progress. ⋯ In addition, Cassigarol A inhibited the plasmin activity and the formation of capillary-like networks of human umbilical vein endothelial cells (HUVECs) at concentrations of 10 to 100 microM. Therefore, it is suggested that the antitumor and antimetastatic activities of Cassigarol A might be due to the inhibition of plasmin activity and formation of tubes (angiogenesis) from HUVECs.
-
Anticancer research · May 2000
An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
The clinical benefit of an intensive follow-up protocol in endometrial cancer patients is still uncertain. ⋯ An intensive surveillance protocol seems to have no significant impact on the outcome of patients with clinical stage I endometrial cancer. Simplified follow-up programs tailored for patient subsets with different recurrence risk are required.